Tech — Hardware
Azenta Executive Compensation (FY25)
AZTA · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): January 29, 2026
284 figures on this page: 273 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
John Marotta was paid $10,371,414 in total compensation as President and Chief Executive Officer for fiscal 2025, and compared with the $638,811 reported for fiscal 2024, Marotta's total was up. For fiscal 2025, shareholders backed the say-on-pay proposal with 96.3% of votes cast for or against in favor at the meeting held January 28, 2026. The disclosed peer group names 10x Genomics, Inc., Bio-Techne Corporation, Certara, Inc., Cryoport, Inc. and Guardant Health, Inc., among others. The company reported 7 named executive officers for fiscal 2025.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — John Marotta: $638,811 → $10,371,414
Say-on-pay support: 99.4% → 96.3% (3.1 points lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Azenta's chief executive and what were they paid?
John Marotta was paid $10,371,414 in total compensation as President and Chief Executive Officer for fiscal 2025. Compared with the $638,811 reported for fiscal 2024, Marotta's total was up.
What was Azenta's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 96.3% of votes cast for or against in favor at the meeting held January 28, 2026.
Which companies are in Azenta's peer group?
The disclosed peer group names 10x Genomics, Inc., Bio-Techne Corporation, Certara, Inc., Cryoport, Inc. and Guardant Health, Inc., among others.
What is Azenta's chief executive pay ratio?
The company reported a chief executive pay ratio of 178.8:1 for fiscal 2025, against median employee compensation of $57,992.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Stephen Schwartz President and Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Lindon Robertson Former Executive Vice President and Chief Financial Officer Departed during or after this year | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Jason Joseph Senior Vice President, General Counsel & Corporate Secretary | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Robin Vacha Senior Vice President, Global Operations | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
David Gray Senior Vice President, Chief Strategy and New Business Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Ginger Zhou Senior Vice President, President GENEWIZ | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Stephen Schwartz Former President and Chief Executive Officer Departed during or after this year | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Herman Cueto Former Executive Vice President and Chief Financial Officer Departed during or after this year | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Jason Joseph Senior Vice President, General Counsel and Corporate Secretary | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Ginger Zhou Senior Vice President & General Manager Multiomics | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
David Wang Senior Vice President & General Manager Sample Management Solutions | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
John Marotta President and Chief Executive Officer | ◇ | — | ◇ | — | — | — | — | ◇ |
Lindon Robertson Former Executive Vice President and Chief Financial Officer Departed during or after this year | ◇ | — | — | — | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
John Marotta President and Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Lawrence Lin Executive Vice President and Chief Financial Officer | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Ephraim Starr Senior Vice President, General Counsel and Corporate Secretary | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Jason Joseph Former Senior Vice President, General Counsel and Corporate Secretary Departed during or after this year | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Olga Pirogova Senior Vice President and Chief Human Resources Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Ginger Zhou Senior Vice President, President GENEWIZ | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Herman Cueto Former Executive Vice President and Chief Financial Officer Departed during or after this year | ◇ | ◇ | — | — | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Ephraim Starr | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Ephraim Starr | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Ginger Zhou | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Ginger Zhou | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Jason W. Joseph | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Jason W. Joseph | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| John Marotta | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| John Marotta | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Lawrence Lin | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Lawrence Lin | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Lawrence Lin | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Olga Pirogova | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Olga Pirogova | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Lawrence Lin | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| John Marotta | PSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Olga Pirogova | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Jason Joseph | PSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Ginger Zhou | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Ephraim Starr | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Frank E. Casal Board chair | ◇ | ◇ | — | — | — | — | ◇ |
Robyn C. Davis | ◇ | ◇ | — | — | — | — | ◇ |
Erica J. McLaughlin | ◇ | ◇ | — | — | — | — | ◇ |
Martin Madaus | ◇ | ◇ | — | — | — | — | ◇ |
Tina S. Nova | ◇ | ◇ | — | — | — | — | ◇ |
Quentin G. Koffey | ◇ | ◇ | — | — | — | — | ◇ |
William L. Cornog | ◇ | ◇ | — | — | — | — | ◇ |
Alan J. Malus | ◇ | ◇ | — | — | — | — | ◇ |
Dipal Doshi | ◇ | ◇ | — | — | — | — | ◇ |
John P. Marotta served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- 10x Genomics, Inc. TXG
- Bio-Techne Corporation TECH
- Certara, Inc. CERT
- Cryoport, Inc. CYRX
- Guardant Health, Inc. GH
- Haemonetics Corporation HAE
- Maravai LifeSciences Holdings Inc. MRVI
- Medpace Holdings, Inc. MEDP
- Myriad Genetics, Inc. MYGN
- Natera, Inc. NTRA
- NeoGenomics, Inc. NEO
- Repligen Corporation RGEN
- Sotera Health Company SHC
- Tandem Diabetes Care, Inc. TNDM
- Twist Bioscience Corporation TWST
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | January 28, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | January 30, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | January 30, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | January 31, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | January 24, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | January 26, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | January 24, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | January 30, 2019 | = | ◇ | ◇ | ◇ |
| 2017 | January 31, 2018 | = | ◇ | ◇ | ◇ |
| 2016 | February 8, 2017 | = | ◇ | ◇ | ◇ |
| 2015 | January 27, 2016 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Azenta disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Azenta sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
284 figures on this page: 273 cited to the filing that reported them, 11 calculated from figures it prints.
273 cited to the filing
11 calculated from the filing
Documents cited
- 0001437749-26-002409
- 0001140361-25-046064COMPENSATION OF DIRECTORS · Director Compensation Table · Grants of Plan Based Awards Table · Outstanding Equity Awards at Fiscal Year End Table · and 1 more section
- 0001437749-25-002824
- 0001140361-24-049734Summary Compensation Table
- 0001558370-24-000691Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001140361-23-057904Summary Compensation Table
- 0001558370-23-000778Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001558370-22-000586Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000933974-21-000002Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000933974-20-000002Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000933974-19-000008Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000933974-18-000004Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000933974-17-000008Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000933974-16-000055Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Azenta executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/AZTA (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Azenta and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Tech — Hardware rankings
Peers Azenta discloses
The companies named in AZTA's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}